Quick answer
Did animal studies of CJC-1295 measure IGF-1? The best-known papers report GH release, plasma persistence, growth, body composition and pituitary GH mRNA; their abstracts do not report IGF-I values for CJC-1295. IGF-I enters the picture through the GHRH knockout mouse, whose abstract documents low serum and liver IGF-I as part of the isolated GH-deficiency phenotype. A careful reader therefore regards IGF-I as the expected downstream marker of the GH axis, and not as a result established for the no-DAC peptide sold by V8 for laboratory research use only.
Searches for “CJC-1295 IGF-1” return a lot of confident text and very few primary data. This article separates what the cited animal papers actually reported from what is inferred from axis biology, and gives a framework for choosing and reading an IGF-I endpoint in a GH-axis model. It does not discuss use outside the laboratory. For laboratory research use only; not for human consumption. It complements, and does not repeat, the methods-focused article on the CJC-1295 and ipamorelin animal studies already in the library and the CJC-1295 No DAC research overview.
The axis in one paragraph
Hypothalamic GHRH stimulates pituitary somatotrophs through the GHRH receptor to make and release GH (Mayo, 1992). GH acts on tissues, most notably the liver, to produce IGF-I, which circulates and mediates many of the growth effects attributed to GH. The classical “somatomedin hypothesis” has been revised since it was proposed: tissue-produced IGF-I also matters locally, and autocrine and paracrine IGF-I are now weighed alongside the circulating hormone (Le Roith and colleagues, 2001). The practical consequence is that a serum IGF-I value is a useful but imperfect integrated readout. It rises and falls over hours to days, not minutes, so it is poorly matched to a short GH pulse.
| Level | Typical measure | Time scale |
|---|---|---|
| Receptor | cAMP in transfected or pituitary cells | Minutes |
| Pituitary output | GH in medium or plasma; GH mRNA; pituitary content | Minutes to days |
| Liver and circulation | Serum IGF-I; liver IGF-I mRNA | Hours to days |
| Whole animal | Body weight, length, organ and bone size | Days to weeks |
The knockout and mutant models that define the readouts
Two mouse models anchor the field. The “little” mouse carries a mutation in the GHRH receptor gene; Lin and colleagues (1993) characterized the molecular basis of its dwarf phenotype, tying receptor function to cell-type-specific growth. The GHRH knockout mouse removes the ligand instead. Alba and Salvatori (2004) created it by replacing the portion of the gene encoding the first 14 residues with a neomycin cassette. Knockout mice appeared normal at birth, grew less from about three weeks, and by 12 weeks weighed about 60% of littermates. Their abstract attributes the growth retardation to isolated GH deficiency, shown by reduced pituitary GH mRNA and protein, reduced serum IGF-I and reduced liver IGF-I mRNA. Heterozygous males had a mild reduction in serum IGF-I.
This is the paper that makes IGF-I a recognized endpoint in the GHRH-deficient background. It is also a reminder that these are models of absent GHRH, a different question from stimulation of a normal axis.
What the CJC-1295 papers reported
| Study | Model | Endpoints reported in the abstract | IGF-I reported? |
|---|---|---|---|
| Jetté and colleagues, 2005 | Cultured rat pituitary cells; normal male rats | GH secretion; 2-hour GH area under the curve; plasma presence beyond 72 h; albumin-associated species | No |
| Alba and colleagues, 2006 | GHRH knockout mice, 5 weeks of exposure starting at 1 week of age | Body weight and length; femur and tibia length; lean and fat mass; pituitary RNA and GH mRNA; somatotroph proliferation by immunohistochemistry | Not in the abstract |
| Clark and Robinson, 1985 (GRF(1-29)NH2, not CJC-1295) | Female rats; GRF-deficient rats | Growth rate; pituitary GH content; GH secretory pattern | Not in the abstract |
In the knockout study, daily CJC-1295 gave normal body weight and length, while administration every 48 or 72 hours gave partial improvement, and the compound increased pituitary GH mRNA (Alba and colleagues, 2006). The paper’s abstract describes growth and body composition, not IGF-I concentrations. Those may appear in the full text, which should be checked by anyone who needs the figure; this article cites only what the abstract establishes. For the no-DAC product, no primary study in this reference list reports IGF-I.
How to use IGF-I as an endpoint
If a laboratory wants an IGF-I readout in a GH-axis experiment, the design questions are practical.
- When to sample. IGF-I integrates GH exposure over hours to days. A single sample after a single pulse will mostly miss it. Repeated exposure schedules, followed by sampling after the last exposure, are the usual match.
- Which fraction. Total serum IGF-I involves binding proteins; assays differ in whether they release the peptide from them. Say which assay and which standard were used.
- Which tissue. Liver IGF-I mRNA reports local production; serum IGF-I reports circulating supply. The knockout paper measured both for this reason (Alba and Salvatori, 2004).
- Which background. A deficient background (the knockout) has a large dynamic range. A normal background has a ceiling, and a null result may reflect feedback and not lack of effect.
- Which controls. Vehicle, positive-control agonist and, where the question is about interaction, single-compound arms (Festing and Altman, 2002).
Choosing the analog for an IGF-I design
The duration of the analog should match the time scale of the endpoint. A long-acting DAC molecule with plasma presence beyond 72 hours in rats (Jetté and colleagues, 2005) gives sustained receptor engagement over the days an IGF-I rise needs. A short-acting no-DAC analog acts in pulses, so an IGF-I design with it has to repeat exposures on a schedule and then document timing precisely. Pulsatile delivery of a short GRF fragment promoted growth in rats whereas continuous delivery at the same daily amount did not (Clark and Robinson, 1985), which shows that exposure pattern, and not only total amount, changes outcomes. The matching logic is laid out in DAC versus no DAC, and the product facts for the no-DAC peptide are on the product page.
Reading claims critically
Three patterns recur in secondary summaries, and each can be checked against the abstracts above.
- “CJC-1295 raised IGF-1 in animals.” None of the abstracts cited here report that. A statement of that kind needs its own primary citation.
- “The no-DAC peptide has the same effects as the DAC peptide for days.” The two molecules differ in persistence by design.
- “GH pulses and IGF-I levels move together.” They move on different time scales, and IGF-I also responds to nutrition and other factors that a study must control.
Further reviews of the neuroendocrine control of GH describe the interplay of GHRH, somatostatin and other inputs that all shape the readout (Giustina and Veldhuis, 1998). Studies that combine a GHRH analog with a secretagogue add the ghrelin-receptor arm; see CJC-1295 and ipamorelin research overview, and for sibling GHRH analogs see the tesamorelin overview and sermorelin overview.
Handling and documentation for an IGF-I study
Because IGF-I experiments run for days or weeks, material handling needs to be consistent across the whole run: one lot where possible, aliquoted stocks, and a written record of reconstitution, storage and thaw history. Dissolving a lyophilized vial follows the general reconstitution method, with concentration equal to mass divided by diluent volume (the calculator does the arithmetic). Certificates, where published, are in the COA library. Storage guidance for the supplied powder is 2–8 °C, or −20 °C for long-term storage, protected from heat, moisture and light.
Frequently asked questions
Did CJC-1295 raise IGF-1 in animal studies?
The abstracts of the principal rodent papers cited here do not report IGF-I values for CJC-1295. They report GH release, plasma persistence, growth, body composition and pituitary GH mRNA. Anyone needing IGF-I data should consult the full texts or run the measurement.
Why is IGF-I linked to GHRH analogs at all?
Because IGF-I is the main downstream mediator of GH in the liver. The GHRH knockout mouse shows reduced serum and liver IGF-I along with low pituitary GH (Alba and Salvatori, 2004).
Can a short GH pulse be seen in IGF-I?
Rarely. IGF-I changes over hours to days and does not follow minute-scale GH pulses, so timing of sampling matters.
What is the GHRH knockout mouse?
A mouse in which the GHRH gene is disrupted. It shows normal birth size, then growth retardation, reaching about 60% of littermate weight by 12 weeks, with isolated GH deficiency.
What did once-daily CJC-1295 do in knockout mice?
In the 5-week study, daily administration gave normal body weight and length and increased pituitary GH mRNA; 48- and 72-hour schedules were less effective (Alba and colleagues, 2006).
Does exposure pattern matter for growth outcomes?
In rats, pulsatile but not continuous infusion of GRF(1-29)NH2 promoted growth (Clark and Robinson, 1985), so pattern matters.
Which analog suits an IGF-I experiment?
A long-acting DAC analog suits sustained exposure, while a short-acting no-DAC analog needs repeated scheduled exposures. The endpoint time scale should decide.
Is serum IGF-I or liver IGF-I mRNA the better readout?
They answer different questions: circulating supply versus local production. Measuring both, as the knockout paper did, gives a fuller picture.
What controls does an IGF-I study need?
Vehicle control, a positive control, a defined sampling schedule and, where interaction is the question, single-compound arms.
Is this guidance for use outside the laboratory?
No. V8 supplies the peptide for laboratory research use only, and this article summarizes published animal work.
Related reading: CJC-1295 Mechanism of Action: GHRH Receptor Signaling, CJC-1295 in Metabolic and Endocrine Research Models, CJC-1295 Pharmacokinetics: Half-Life Explained.
References
- Mayo KE. Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol Endocrinol. 1992;6(10):1734-1744. doi:10.1210/mend.6.10.1333056
- Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53-74. doi:10.1210/edrv.22.1.0419
- Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature. 1993;364(6434):208-213. doi:10.1038/364208a0
- Alba M, Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated GH deficiency. Endocrinology. 2004;145(9):4134-4143. doi:10.1210/en.2004-0119
- Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0
- Festing MFW, Altman DG. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 2002;43(4):244-258. doi:10.1093/ilar.43.4.244
